NCT06181370View on ClinicalTrials.gov

Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

PHASE1RecruitingINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

IPF

Interventions

DRUG

AGMB-447

AGMB-447 inhaled drug

OTHER

placebo

placebo inhaled drug

Trial Locations (1)

M23 9QZ

RECRUITING

Medicines Evaluation Unit, Manchester

All Listed Sponsors

lead

Agomab Spain S.L.

INDUSTRY